Stay updated on Pembrolizumab in NSCLC with PS 2 Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in NSCLC with PS 2 Clinical Trial page.

Latest updates to the Pembrolizumab in NSCLC with PS 2 Clinical Trial page
- Check5 days agoChange Detected- Revision updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 was added. The earlier notice Revision: v3.4.1 and related government funding/operating status notices were removed.SummaryDifference0.4%

- Check41 days agoChange DetectedA site-wide notice about government funding status and a new revision tag (v3.4.1) were added, replacing the previous v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedUI and metadata updates include showing the glossary and adding the QC-related label 'Last Update Submitted that Met QC Criteria' and the revision tag 'Revision: v3.4.0'. The earlier QC label, 'No FEAR Act data,' and 'Revision: v3.3.4' text are removed or updated accordingly.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded new study locations: Greater Manchester, Hampshire, Kent, and West Midlands, with the page revision updated to v3.3.3.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab in NSCLC with PS 2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in NSCLC with PS 2 Clinical Trial page.